140 related articles for article (PubMed ID: 19148520)
1. Differential enhancement of the anti-cancer effect of doxorubicin by Akt inhibitors on human breast cancer cells with differing genetic backgrounds.
Wang YA; Johnson SK; Brown BL; Dobson PR
Oncol Rep; 2009 Feb; 21(2):437-42. PubMed ID: 19148520
[TBL] [Abstract][Full Text] [Related]
2. Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status.
Wang YA; Johnson SK; Brown BL; McCarragher LM; Al-Sakkaf K; Royds JA; Dobson PR
Int J Cancer; 2008 Oct; 123(7):1536-44. PubMed ID: 18634052
[TBL] [Abstract][Full Text] [Related]
3. Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells.
Li X; Lu Y; Liang K; Liu B; Fan Z
Breast Cancer Res; 2005; 7(5):R589-97. PubMed ID: 16168102
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
5. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.
Kozar K; Kaminski R; Legat M; Kopec M; Nowis D; Skierski JS; Koronkiewicz M; Jakóbisiak M; Golab J
Int J Oncol; 2004 May; 24(5):1149-57. PubMed ID: 15067336
[TBL] [Abstract][Full Text] [Related]
6. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
Tyagi AK; Agarwal C; Chan DC; Agarwal R
Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel-doxorubicin sequence is more effective in breast cancer cells with heat shock protein 27 overexpression.
Shi P; Wang MM; Jiang LY; Liu HT; Sun JZ
Chin Med J (Engl); 2008 Oct; 121(20):1975-9. PubMed ID: 19080259
[TBL] [Abstract][Full Text] [Related]
8. Proliferation of human breast cancer cells and anti-cancer action of doxorubicin and vinblastine are independent of PKC-alpha.
Liu DS; Krebs CE; Liu SJ
J Cell Biochem; 2007 May; 101(2):517-28. PubMed ID: 17171646
[TBL] [Abstract][Full Text] [Related]
9. Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.
Wallin JJ; Guan J; Prior WW; Edgar KA; Kassees R; Sampath D; Belvin M; Friedman LS
Sci Transl Med; 2010 Sep; 2(48):48ra66. PubMed ID: 20826841
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
Hu C; Solomon VR; Ulibarri G; Lee H
Bioorg Med Chem; 2008 Sep; 16(17):7888-93. PubMed ID: 18691894
[TBL] [Abstract][Full Text] [Related]
11. Kalopanaxsaponin A inhibits PMA-induced invasion by reducing matrix metalloproteinase-9 via PI3K/Akt- and PKCdelta-mediated signaling in MCF-7 human breast cancer cells.
Park SK; Hwang YS; Park KK; Park HJ; Seo JY; Chung WY
Carcinogenesis; 2009 Jul; 30(7):1225-33. PubMed ID: 19420016
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cells.
Liang J; Ge F; Guo C; Luo G; Wang X; Han G; Zhang D; Wang J; Li K; Pan Y; Yao L; Yin Z; Guo X; Wu K; Ding J; Fan D
FEBS J; 2009 Feb; 276(3):685-94. PubMed ID: 19143835
[TBL] [Abstract][Full Text] [Related]
13. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
Foroodi F; Duivenvoorden WC; Singh G
Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatics-based discovery and characterization of an AKT-selective inhibitor 9-chloro-2-methylellipticinium acetate (CMEP) in breast cancer cells.
Zhang M; Fang X; Liu H; Guo R; Wu X; Li B; Zhu F; Ling Y; Griffith BN; Wang S; Yang D
Cancer Lett; 2007 Jul; 252(2):244-58. PubMed ID: 17293030
[TBL] [Abstract][Full Text] [Related]
15. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
16. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc.
Bidwell GL; Raucher D
Biochem Pharmacol; 2006 Jan; 71(3):248-56. PubMed ID: 16316634
[TBL] [Abstract][Full Text] [Related]
18. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
[TBL] [Abstract][Full Text] [Related]
19. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin.
Hoke EM; Maylock CA; Shacter E
Free Radic Biol Med; 2005 Aug; 39(3):403-11. PubMed ID: 15993339
[TBL] [Abstract][Full Text] [Related]
20. Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells.
Sharma G; Tyagi AK; Singh RP; Chan DC; Agarwal R
Breast Cancer Res Treat; 2004 May; 85(1):1-12. PubMed ID: 15039593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
